V V Bumialis

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Clinical trials of the gene engineered human alpha 2-interferon as ointment were performed. The ointment was used in the treatment of patients with relapsing herpes of various localization, relapsing aphthous stomatitis and pemphigus vulgaris. It was shown that the ointment was harmless and its therapeutic effect was favourable. The preparation is(More)
The results of the clinical trials of human recombinant interferon alpha-2 (reaferon) make it possible to come to the conclusion that the preparation is well-tolerated and produces a pronounced therapeutic effect in a number of viral and oncological diseases. The Pharmacological Committee of the USSR has recommended reaferon for use in acute hepatitis B,(More)
Employment of isoelectrofocussing techniques for the determination of proteinase alpha 1-inhibitor (p alpha 1i) phenotypes helped detect original rare phenotypes. Their accurate identification should be performed with a set of standard sera. The findings of studies on the number of p alpha 1i by Mancini's immunoprecipitation test are analyzed, as are the(More)
Using stepwise ion-exchange and gel-permeation high performance liquid chromatography and SDS-PAAG gel electrophoresis, it was demonstrated that the non-reduced gene-engineered interferon alpha A is represented by multiple forms, namely, four monomers, four dimers, two trimers and one tetramer. All the protein forms were obtained in an individual state and(More)
The ability of recombinant alpha 2-interferon (reaferon) to compete for opiate binding sites with mu- and delta-selective compounds was determined. Reaferon was found to inhibit the binding of 3H-D-ala2, D-leu5-enkephalin, and Ki value calculated was equal to 8.5 +/- 2.6 U.10(-3)/ml. The mu-agonists reception levels were decreased in the presence of(More)
  • 1